Takeda Canada, Inc. has reacquired Canadian commercial rights to Actos, an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda licensed the drug to Lilly in 1999 as part of a worldwide agreement.
"Reacquiring the commercial rights to Actos is Takeda's first opportunity to establish a commercial presence in Canada," said Daaron Dohler, general manager at Takeda Canada. "It also underscores Takeda's ongoing efforts to reinforce our global operations and build a stronger presence in North America."
Actos was approved by Health Canada as monotherapy to decrease insulin resistance and blood glucose levels in patients with type 2 diabetes mellitus, in September 2000. Takeda took over responsibility for the drug in the Canadian market in mid-June, and currently sells it in other territories, including the U.S., Japan and most of Europe.
Sign up today for Contracting & Outsourcing 2009!